Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [[maximum depth reached]]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-trace').style.display = (document.getElementById('cakeErr6801575cbd117-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801575cbd117-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-code').style.display = (document.getElementById('cakeErr6801575cbd117-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-context').style.display = (document.getElementById('cakeErr6801575cbd117-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801575cbd117-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801575cbd117-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26287,
		&#039;title&#039; =&gt; &#039;Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Total funding needed to fight TB = $9.8 billion (2011-15)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Actual funding = $1.99 billion (till Dec 2013)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Share of TB Research Funding
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Public: 59%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Philanthropic: 25%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Private: 15%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Multilateral: 1% 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674325,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26287,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Total funding needed to fight TB = $9.8 billion (2011-15)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Actual funding = $1.99 billion (till Dec 2013)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Share of TB Research Funding&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Public: 59%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Philanthropic: 25%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Private: 15%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Multilateral: 1% &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26287,
	&#039;title&#039; =&gt; &#039;Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Total funding needed to fight TB = $9.8 billion (2011-15)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Actual funding = $1.99 billion (till Dec 2013)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Share of TB Research Funding
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Public: 59%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Philanthropic: 25%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Private: 15%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Multilateral: 1% 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674325,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {},
		(int) 9 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26287
$metaTitle = &#039;LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;
$metaKeywords = &#039;medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB&#039;
$metaDesc = &#039;
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Total funding needed to fight TB = $9.8 billion (2011-15)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Actual funding = $1.99 billion (till Dec 2013)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Share of TB Research Funding&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Public: 59%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Philanthropic: 25%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Private: 15%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Multilateral: 1% &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma | Im4change.org</title>
    <meta name="description" content="
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify">Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.</p><p align="justify">Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).</p><p align="justify">The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.</p><p align="justify">India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp; Melinda Gates Foundation which spent $147.9 million.</p><p align="justify">New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.</p><p align="justify">&quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&quot; he told TOI.</p><p align="justify">According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.</p><p align="justify">India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.</p><p align="justify">Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India.</p><p align="justify">&quot;Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&quot; he said.</p><p align="justify">Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind.</p><p align="justify">&quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&quot; Frick said.</p><p align="justify">Total funding needed to fight TB = $9.8 billion (2011-15)</p><p align="justify">Actual funding = $1.99 billion (till Dec 2013)</p><p align="justify">Share of TB Research Funding</p><p align="justify">Public: 59%</p><p align="justify">Philanthropic: 25%</p><p align="justify">Private: 15%</p><p align="justify">Multilateral: 1% </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-trace').style.display = (document.getElementById('cakeErr6801575cbd117-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801575cbd117-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-code').style.display = (document.getElementById('cakeErr6801575cbd117-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-context').style.display = (document.getElementById('cakeErr6801575cbd117-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801575cbd117-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801575cbd117-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26287,
		&#039;title&#039; =&gt; &#039;Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Total funding needed to fight TB = $9.8 billion (2011-15)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Actual funding = $1.99 billion (till Dec 2013)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Share of TB Research Funding
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Public: 59%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Philanthropic: 25%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Private: 15%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Multilateral: 1% 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674325,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26287,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Total funding needed to fight TB = $9.8 billion (2011-15)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Actual funding = $1.99 billion (till Dec 2013)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Share of TB Research Funding&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Public: 59%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Philanthropic: 25%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Private: 15%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Multilateral: 1% &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26287,
	&#039;title&#039; =&gt; &#039;Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Total funding needed to fight TB = $9.8 billion (2011-15)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Actual funding = $1.99 billion (till Dec 2013)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Share of TB Research Funding
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Public: 59%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Philanthropic: 25%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Private: 15%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Multilateral: 1% 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674325,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {},
		(int) 9 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26287
$metaTitle = &#039;LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;
$metaKeywords = &#039;medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB&#039;
$metaDesc = &#039;
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Total funding needed to fight TB = $9.8 billion (2011-15)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Actual funding = $1.99 billion (till Dec 2013)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Share of TB Research Funding&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Public: 59%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Philanthropic: 25%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Private: 15%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Multilateral: 1% &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma | Im4change.org</title>
    <meta name="description" content="
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify">Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.</p><p align="justify">Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).</p><p align="justify">The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.</p><p align="justify">India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp; Melinda Gates Foundation which spent $147.9 million.</p><p align="justify">New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.</p><p align="justify">&quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&quot; he told TOI.</p><p align="justify">According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.</p><p align="justify">India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.</p><p align="justify">Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India.</p><p align="justify">&quot;Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&quot; he said.</p><p align="justify">Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind.</p><p align="justify">&quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&quot; Frick said.</p><p align="justify">Total funding needed to fight TB = $9.8 billion (2011-15)</p><p align="justify">Actual funding = $1.99 billion (till Dec 2013)</p><p align="justify">Share of TB Research Funding</p><p align="justify">Public: 59%</p><p align="justify">Philanthropic: 25%</p><p align="justify">Private: 15%</p><p align="justify">Multilateral: 1% </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-trace').style.display = (document.getElementById('cakeErr6801575cbd117-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr6801575cbd117-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-code').style.display = (document.getElementById('cakeErr6801575cbd117-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr6801575cbd117-context').style.display = (document.getElementById('cakeErr6801575cbd117-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr6801575cbd117-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr6801575cbd117-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 26287,
		&#039;title&#039; =&gt; &#039;Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Total funding needed to fight TB = $9.8 billion (2011-15)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Actual funding = $1.99 billion (till Dec 2013)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Share of TB Research Funding
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Public: 59%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Philanthropic: 25%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Private: 15%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Multilateral: 1% 
&lt;/p&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4674325,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 26287,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Total funding needed to fight TB = $9.8 billion (2011-15)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Actual funding = $1.99 billion (till Dec 2013)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Share of TB Research Funding&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Public: 59%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Philanthropic: 25%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Private: 15%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Multilateral: 1% &lt;/p&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 26287,
	&#039;title&#039; =&gt; &#039;Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Times of India
&lt;/div&gt;
&lt;p align=&quot;justify&quot;&gt;
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Total funding needed to fight TB = $9.8 billion (2011-15)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Actual funding = $1.99 billion (till Dec 2013)
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Share of TB Research Funding
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Public: 59%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Philanthropic: 25%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Private: 15%
&lt;/p&gt;
&lt;p align=&quot;justify&quot;&gt;
Multilateral: 1% 
&lt;/p&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4674325,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {},
		(int) 7 =&gt; object(Cake\ORM\Entity) {},
		(int) 8 =&gt; object(Cake\ORM\Entity) {},
		(int) 9 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 26287
$metaTitle = &#039;LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma&#039;
$metaKeywords = &#039;medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB&#039;
$metaDesc = &#039;
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Times of India&lt;/div&gt;&lt;p align=&quot;justify&quot;&gt;Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp;amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp;amp; Melinda Gates Foundation which spent $147.9 million.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&amp;quot; he told TOI.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists&#039; network in India.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;Thirty seven percent of the global pharma market is in the US while India&#039;s share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don&#039;t want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&amp;quot; he said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don&#039;t receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma&#039;s mind.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;&amp;quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&amp;quot; Frick said.&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Total funding needed to fight TB = $9.8 billion (2011-15)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Actual funding = $1.99 billion (till Dec 2013)&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Share of TB Research Funding&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Public: 59%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Philanthropic: 25%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Private: 15%&lt;/p&gt;&lt;p align=&quot;justify&quot;&gt;Multilateral: 1% &lt;/p&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma | Im4change.org</title>
    <meta name="description" content="
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Times of India</div><p align="justify">Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.</p><p align="justify">Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).</p><p align="justify">The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.</p><p align="justify">India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp; Melinda Gates Foundation which spent $147.9 million.</p><p align="justify">New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.</p><p align="justify">&quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&quot; he told TOI.</p><p align="justify">According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.</p><p align="justify">India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.</p><p align="justify">Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India.</p><p align="justify">&quot;Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&quot; he said.</p><p align="justify">Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind.</p><p align="justify">&quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&quot; Frick said.</p><p align="justify">Total funding needed to fight TB = $9.8 billion (2011-15)</p><p align="justify">Actual funding = $1.99 billion (till Dec 2013)</p><p align="justify">Share of TB Research Funding</p><p align="justify">Public: 59%</p><p align="justify">Philanthropic: 25%</p><p align="justify">Private: 15%</p><p align="justify">Multilateral: 1% </p>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 26287,
		'title' => 'Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma',
		'subheading' => '',
		'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
</p>
<p align="justify">
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
</p>
<p align="justify">
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
</p>
<p align="justify">
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp; Melinda Gates Foundation which spent $147.9 million.
</p>
<p align="justify">
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
</p>
<p align="justify">
&quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&quot; he told TOI.
</p>
<p align="justify">
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
</p>
<p align="justify">
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
</p>
<p align="justify">
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India.
</p>
<p align="justify">
&quot;Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&quot; he said.
</p>
<p align="justify">
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind.
</p>
<p align="justify">
&quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&quot; Frick said.
</p>
<p align="justify">
Total funding needed to fight TB = $9.8 billion (2011-15)
</p>
<p align="justify">
Actual funding = $1.99 billion (till Dec 2013)
</p>
<p align="justify">
Share of TB Research Funding
</p>
<p align="justify">
Public: 59%
</p>
<p align="justify">
Philanthropic: 25%
</p>
<p align="justify">
Private: 15%
</p>
<p align="justify">
Multilateral: 1% 
</p>',
		'credit_writer' => 'The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4674325,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 26287,
	'metaTitle' => 'LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma',
	'metaKeywords' => 'medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB',
	'metaDesc' => '
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...',
	'disp' => '<div align="justify">-The Times of India</div><p align="justify">Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.</p><p align="justify">Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).</p><p align="justify">The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.</p><p align="justify">India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp; Melinda Gates Foundation which spent $147.9 million.</p><p align="justify">New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.</p><p align="justify">&quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&quot; he told TOI.</p><p align="justify">According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.</p><p align="justify">India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.</p><p align="justify">Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India.</p><p align="justify">&quot;Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&quot; he said.</p><p align="justify">Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind.</p><p align="justify">&quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&quot; Frick said.</p><p align="justify">Total funding needed to fight TB = $9.8 billion (2011-15)</p><p align="justify">Actual funding = $1.99 billion (till Dec 2013)</p><p align="justify">Share of TB Research Funding</p><p align="justify">Public: 59%</p><p align="justify">Philanthropic: 25%</p><p align="justify">Private: 15%</p><p align="justify">Multilateral: 1% </p>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 26287,
	'title' => 'Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma',
	'subheading' => '',
	'description' => '<div align="justify">
-The Times of India
</div>
<p align="justify">
Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.
</p>
<p align="justify">
Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).
</p>
<p align="justify">
The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.
</p>
<p align="justify">
India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp; Melinda Gates Foundation which spent $147.9 million.
</p>
<p align="justify">
New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.
</p>
<p align="justify">
&quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&quot; he told TOI.
</p>
<p align="justify">
According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.
</p>
<p align="justify">
India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.
</p>
<p align="justify">
Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India.
</p>
<p align="justify">
&quot;Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&quot; he said.
</p>
<p align="justify">
Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind.
</p>
<p align="justify">
&quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&quot; Frick said.
</p>
<p align="justify">
Total funding needed to fight TB = $9.8 billion (2011-15)
</p>
<p align="justify">
Actual funding = $1.99 billion (till Dec 2013)
</p>
<p align="justify">
Share of TB Research Funding
</p>
<p align="justify">
Public: 59%
</p>
<p align="justify">
Philanthropic: 25%
</p>
<p align="justify">
Private: 15%
</p>
<p align="justify">
Multilateral: 1% 
</p>',
	'credit_writer' => 'The Times of India, 25 October, 2014, http://timesofindia.indiatimes.com/india/Pvt-sector-deserts-war-on-TB-funding-down-33-since-2011/articleshow/44928595.cms',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'pvt-sector-deserts-war-on-tb-funding-down-33-since-2011-subodh-varma-4674325',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4674325,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {},
		(int) 7 => object(Cake\ORM\Entity) {},
		(int) 8 => object(Cake\ORM\Entity) {},
		(int) 9 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 26287
$metaTitle = 'LATEST NEWS UPDATES | Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma'
$metaKeywords = 'medicine,medicines,Health,health issues,healthcare,healthcare in india,Public Health,Public health crisis,Tuberculosis,TB'
$metaDesc = '
-The Times of India


Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than...'
$disp = '<div align="justify">-The Times of India</div><p align="justify">Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes.</p><p align="justify">Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO).</p><p align="justify">The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013.</p><p align="justify">India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy &amp; Infectious Diseases of US which invested over $158.8 million, followed by the Bill &amp; Melinda Gates Foundation which spent $147.9 million.</p><p align="justify">New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB.</p><p align="justify">&quot;There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy,&quot; he told TOI.</p><p align="justify">According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities.</p><p align="justify">India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases.</p><p align="justify">Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India.</p><p align="justify">&quot;Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people,&quot; he said.</p><p align="justify">Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind.</p><p align="justify">&quot;TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing,&quot; Frick said.</p><p align="justify">Total funding needed to fight TB = $9.8 billion (2011-15)</p><p align="justify">Actual funding = $1.99 billion (till Dec 2013)</p><p align="justify">Share of TB Research Funding</p><p align="justify">Public: 59%</p><p align="justify">Philanthropic: 25%</p><p align="justify">Private: 15%</p><p align="justify">Multilateral: 1% </p>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Pvt sector deserts war on TB, funding down 33% since 2011 -Subodh Varma

-The Times of India Even as tuberculosis (TB) continues to haunt the world, a new study has revealed that funding for research and development of new drugs to fight the disease is floundering. Private sector funding has declined by more than a third since 2011 as pharma companies are closing their TB research programmes. Pfizer shut down its TB drug discovery programme in 2012, AstraZeneca in 2013 and Novartis in 2014. Meanwhile, multi-drug resistant TB is rapidly spreading with 450,000-odd new cases reported in 2012 by the World Health Organisation (WHO). The report was prepared by Treatment Action Group (TAG), a New York based health policy think tank. It pointed out that while $9.8 billion was needed to fight TB during 2011-2015 according to a Global Plan prepared by experts in 2011, the world spent only $1.99 billion by the end of 2013. India spent around $7.6 million in 2013 on TB research according to the TAG report. The highest spender was the National Institute of Allergy & Infectious Diseases of US which invested over $158.8 million, followed by the Bill & Melinda Gates Foundation which spent $147.9 million. New drugs are needed because current drugs require a six-month course increasing chances of patients not finishing it and thus relapsing, explained Mike Fricke, author of the TAG report. Also, new drugs are essential to fight the growing incidence of drug-resistant TB. "There is a great need for shorter treatment regimens using fewer numbers of pills. The current regimen requires six months of treatment... making it difficult for many patients to finish therapy. For drug-resistant TB, there is an urgent need to develop safer, more tolerable drugs. Many of the drugs used to treat drug-resistant TB are decades old and carry severe toxicities including hearing loss, psychosis and peripheral neuropathy," he told TOI. According to the TAG report, the onus of developing new treatments for TB is now falling more on public funding. Over 60 percent of global TB research is now done under public funded programs in research institutions and universities. India is one of the more severely TB-affected countries with about 2.8 million TB patients including 55,000 multi-drug resistant TB cases. Why is the private sector deserting this war? They do not see much profit in TB drugs because this is a disease most widely prevalent in middle and lower income countries, says Amit Sengupta of the Jan Swasthya Abhiyan, a health activists' network in India. "Thirty seven percent of the global pharma market is in the US while India's share is just 2%. Big Pharma prefers making and selling drugs needed by the richer countries for ailments like heart diseases, cancer, depression. They don't want to spend money on drugs and vaccines for TB or malaria which afflict millions of poorer people," he said. Each year 3 million of the nearly 9 million people who get TB are never reported to national TB programs and don't receive a diagnosis or treatment, says Frick. This deficiency in the healthcare system is also weighing on Big Pharma's mind. "TB affected communities will be asked to pay twice - first to fund the research behind new drugs and then again to buy those drugs back from the same pharmaceutical companies that benefited from public financing," Frick said. Total funding needed to fight TB = $9.8 billion (2011-15) Actual funding = $1.99 billion (till Dec 2013) Share of TB Research Funding Public: 59% Philanthropic: 25% Private: 15% Multilateral: 1%